Welcome to our dedicated page for Precision Biosciences SEC filings (Ticker: DTIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precision BioSciences’ ARCUS genome-editing breakthroughs look exciting—until you hit the 300-page disclosure explaining clinical trial data, FDA feedback, and milestone accounting. If finding pipeline updates or cash-runway details in a biotech 10-K feels like lab work, you’re not alone.
Stock Titan decodes every DTIL annual report 10-K simplified and DTIL quarterly earnings report 10-Q filing the moment they appear on EDGAR. Our AI highlights where the company reports dose-escalation results, collaboration revenue, and new GMP manufacturing spend, turning DTIL SEC filings explained simply from wishful thinking into reality. Need material news fast? See DTIL 8-K material events explained minutes after submission, or track DTIL Form 4 insider transactions real-time—including DTIL executive stock transactions Form 4—before the market reacts.
What investors actually do with this data:
- Compare R&D burn rates quarter-over-quarter using our DTIL earnings report filing analysis
- Monitor DTIL insider trading Form 4 transactions for confidence signals ahead of trial read-outs
- Review the DTIL proxy statement executive compensation section to align incentives
The result? You spend minutes, not hours, understanding DTIL SEC documents with AI. Every filing type, every footnote, delivered in real time—so you can focus on whether ARCUS is truly a cut above the rest.
Precision BioSciences (NASDAQ: DTIL) filed a Form 4 reporting that director Melinda Brown purchased 1,682 common shares on June 25 2025 at a weighted-average price of $4.14–$4.15. Following the transaction, Brown’s direct beneficial ownership increased to 20,565 shares.
No other non-derivative or derivative transactions were disclosed, and there were no sales. The filing contains a standard footnote explaining the weighted-average price range. No 10b5-1 trading plan box was checked.
Precision BioSciences (NASDAQ: DTIL) filed a Form 4 disclosing that director Kevin Buehler purchased 5,076 shares of common stock on 25 Jun 2025 at a weighted-average price of $4.16 per share (trade range: $4.16–$4.18). After the transaction, Buehler directly owns 28,137 shares, an increase of roughly 22% in his personal stake. The transaction was coded “P” for an open-market purchase, and the filing reports no sales or derivative security activity. No Rule 10b5-1 trading plan was indicated.
FAQ
What is the current stock price of Precision Biosciences (DTIL)?
What is the market cap of Precision Biosciences (DTIL)?
What is the primary focus of Precision Biosciences?
How does the ARCUS genome editing platform differentiate from traditional methods?
In which markets does Precision Biosciences operate?
What role do collaborations play in the company’s strategy?
How does Precision Biosciences ensure the safety and efficacy of its products?
What makes the ARCUS platform a unique tool in genome editing?
How is Precision Biosciences positioned within the competitive biotechnology landscape?
What are the potential applications of the ARCUS platform beyond human therapeutics?
